Last $2.60 USD
Change Today +0.03 / 1.17%
Volume 155.2K
CNDO On Other Exchanges
As of 8:10 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

coronado biosciences inc (CNDO) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/15 - $2.88
52 Week Low
08/8/14 - $1.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

coronado biosciences inc (CNDO) Related Bloomberg News

View More Bloomberg News

coronado biosciences inc (CNDO) Related Businessweek News

No Related Businessweek News Found

coronado biosciences inc (CNDO) Details

Coronado Biosciences, Inc., a development stage biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. The company's principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201, a biologic comprising the microscopic eggs of the porcine whipworm for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis, multiple sclerosis, autism, psoriasis, and type 1 diabetes; and CNDO-109, a biologic that activates the immune system’s natural killer cells to seek and destroy cancer cells for the treatment of acute myeloid leukemia. Coronado Biosciences, Inc. has strategic alliances and commercial agreements with Ovamed GmbH, Dr. Falk Pharma GmbH, Freie Universität Berlin, UCL Business PCL, and Progenitor Cell Therapy. The company was founded in 2006 and is based in Burlington, Massachusetts.

14 Employees
Last Reported Date: 03/14/14
Founded in 2006

coronado biosciences inc (CNDO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $980.0
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $540.8K
Senior Vice President of Biologics Operations
Total Annual Compensation: $250.3K
Compensation as of Fiscal Year 2013.

coronado biosciences inc (CNDO) Key Developments

Coronado Biosciences, Inc. Obtains License from Revogenex Ireland Ltd

Coronado Biosciences, Inc. has obtained an exclusive license to an intravenous (IV) formulation of tramadol for the U.S. market from Revogenex Ireland Ltd. Coronado has formed a wholly owned subsidiary, Avenue Therapeutics, Inc., to acquire, in-license, develop and commercialize products principally for use in the U.S. hospital market. Coronado will transfer the Revogenex license to Avenue Therapeutics, Inc. In addition to IV tramadol, Avenue Therapeutics plans to seek additional products. Tramadol is a centrally acting synthetic opioid analgesic for moderate to moderately severe pain. It is available as immediate release or extended-release tablets in the U.S. It has been reported that oral tramadol sales were approximately $1.2 billion in the U.S. in 2014. Avenue Therapeutics plans to initiate a Phase III development program of IV tramadol for the management of post-operative pain later this year. Under the terms of the agreement, Coronado and Avenue Therapeutics will assume sole responsibility for the development and commercialization of IV tramadol in the U.S. Revogenex received an upfront payment of $2 million upon execution of the exclusive license and is eligible to receive additional milestone payments upon the achievement of certain development milestones, in addition to royalty payments for sales of the product.

Coronado Biosciences, Inc. Announces Earnings Results for the Third Quarter Ended and Nine Months Ended September 30, 2014

Coronado Biosciences, Inc. announced earnings results for the third quarter ended and nine months ended September 30, 2014. For the quarter, the company reported net loss of $4.6 million or $0.13 per basic and diluted share compared to a net loss of $7.832 million or $0.24 per basic and diluted share for the same period a year ago. Loss from operations was $4,436,000 against $7,504,000 a year ago. For the nine months, the company reported net loss of $16.673 million or $0.46 per basic and diluted share compared to $27.360 million or $0.95 per basic and diluted share for the same period a year ago. Loss from operations was $15,691,000 against $26,256,000 a year ago.

Coronado Biosciences, Inc. Forms Wholly Owned Subsidiary Journey Medical Corporation; Announces Executive Appointment for Journey Medical Corporation

Coronado Biosciences, Inc. has formed a wholly owned subsidiary, Journey Medical Corporation (JMC), to acquire and license dermatology products. Under the leadership of Claude Maraoui, CEO, JMC will begin building a portfolio of dermatological assets focused on acne, steroid responsive dermatoses, pigmentation and antifungals for promotion to dermatologists and pediatricians. Mr. Maraoui has more than 25 years of experience in commercializing dermatology products. He was formerly Vice President, Dermatology Sales and Executive Director of Aesthetics Sales at Medicis Pharmaceutical Corporation.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CNDO:US $2.60 USD +0.03

CNDO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CNDO.
View Industry Companies

Industry Analysis


Industry Average

Valuation CNDO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORONADO BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at